Status:
UNKNOWN
Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)
Lead Sponsor:
Aichi Gakuin University
Conditions:
Diabetes Mellitus
Impaired Glucose Tolerance
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
The objective of this trial is to investigate the effect of early treatment of glucose toxicity with acarbose, a drug to control postprandial hyperglycemia, on the occurence of cardiovascular events a...
Detailed Description
Acarbose suppresses the postprandial increase in plasma glucose levels by inhibiting the activities of alpha-amylase and alpha-glucosidase involved in digestion and absorption of carbohydrates in the ...
Eligibility Criteria
Inclusion
- Patients who have been diagnosed with coronary artery disease, with type 2 diabetes or impaired glucose tolerance
Exclusion
- Patients scheduled to undergo revascularization at the time of enrollment
- Patients who are being treated with an oral hypoglycemic drug or an insulin preparation
- Patients with a history of laparotomy of ileus
- Pre- and postoperative patients or individuals with severe infection or serious trauma
- Patients with gastrointestinal disorders such as diarrhea and vomiting
- Patients with a history of hypersensitivity to acarbose
- Pregnant or possibly pregnant women
- Patients who are judged by the attending physician to be otherwise ineligible
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2013
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00858676
Start Date
April 1 2009
End Date
March 1 2013
Last Update
July 18 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University
Nagoya, Japan, 464-8650